Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: Multicenter, controlled, observational cohort study

Journal of the Society for Integrative Oncology

Volumn 7, Issue 4, 2009, Pages 137-145

  Friedel, Walter E ^a   Matthes, Harald ^b   Bock, Paul R ^c   Zänker, Kurt S ^d  

^a Hospital Bad Bocklet   (Germany)

^b Research Institute Havelhöhe FIH Havelhöhe Hospital   (Germany)

^c IFAG Basel AG   (Switzerland)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Colorectal carcinoma; Mistletoe; Observational cohort study; Quality of life; Supportive care therapy; Survival

Indexed keywords

FLUOROURACIL; VISCUM ALBUM EXTRACT;

ADULT; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; OBSERVATIONAL STUDY; PAIN; PARALLEL DESIGN; PRURITUS; RETROSPECTIVE STUDY; SYSTEMIC DISEASE; TINNITUS;

CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MISTLETOE; MULTIVARIATE ANALYSIS; ODDS RATIO; PHYTOTHERAPY; PLANT EXTRACTS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SWITZERLAND; TIME FACTORS;

EID: 76749158966     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2009.0014     Document Type: Article

References (26)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. American Cancer Society. Cancer facts & fi gures 2008. Atlanta (GA): American Cancer Society; 2008.
3. Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006; 17: 1347-59.
4. Benson AB III, Schrag D, Somerfi eld MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
5. Kahlenberg MS, Rousseau DL, Strasser J, et al. Rectal cancer: management of locoregional disease. In: Kelsen DP, Daly JM, Kern SE, et al, editors. Principles and practice of gastrointestinal oncology. 2nd ed. Philadelphia: Wolter Kluver-Lippincott Williams & Wilkins; 2008. p. 593-615.
6. Eder JP, Skarin AT. Systemic and mucocutaneous reactions to chemotherapy. In: Meyerhardt J, Saunders M, Skarin AT, editors. Colorectal cancer. 1st ed. Edinburgh: Mosby Elsevier; 2007. p. 57-104.
7. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25: 424-30.
8. Arndt V, Merx H, Stegmaier C, et al. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a populationbased study. J Clin Oncol 2004; 22: 4829-36.
9. Ludwig H, Zojer N. Supportive care. Ann Oncol 2007; 18 Suppl 1: i37-44.
10. Horneber M, Bueschel G, Huber R, et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; (2): CD003297.
11. European Union, European Parliament, European Council. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to human medicinal products. Official Journal of the European Communities 2001; L 311: 67-128.
12. Schneider B. Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother Pharmacol 2001; 47 Suppl: 35-7.
13. Benson K, Hartz AJ. A comparison of observational studies and randomized clinical trials. N Engl J Med 2000; 342: 1878-86.
14. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research design. N Engl J Med 2000; 342: 1887-92.
15. Heinrich M, Seegenschmied MH, Müller RP, et al. Common Toxicity Criteria (CTC). Dokumentation von Nebenwirkungen in der Onkologie. Dtsch Ärzteblatt 1999; 96: 355-60.
16. Buyse M, Burzykowski T, Carroll K, et al. Progressionfree survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-24.
17. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25: 4569-74.
18. Rosenbaum PR. Observational studies. 2nd ed. New York: Springer-Verlag; 2002.
19. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990; 89: 630-8.
20. Breslow NE, Day NE. Statistical methods in cancer research. Vol II. The design and analysis of cohort studies. Lyon: World Health Organization; International Agency for Research On Cancer; 1987. IARC Scientific Publications No.: 82.
21. Feinstein AR. The role of observational studies in the evaluation of therapy. Stat Med 1984; 3: 341-5.
22. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to non-randomized control group. Stat Med 1998; 17: 2265-81.
23. Kienle GS, Kiene H. [Mistletoe in the Oncology. Facts and conceptual basis]. Stuttgart: Schattauer; 2003.
24. Pasqualini CD, Mihich E, Zänker KS, editors. New directions in cancer management. Medicina (B Aires) 2007; 67 Suppl II: 1-118.
25. Ramaekers FC, Harsma M, Tusenius KJ, et al. Mistletoe extracts (Viscum album L.) Iscador® interact with the cell cycle machinery and target survival mechanisms in cancer cells. Medicina 2007; 67 Suppl II: 79-84.
26. Velikova G, Wright P, Smith AB, et al. Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol 2001; 19: 2064-73.